Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Oral Vinorelbine in NSCLC and Mesothelioma
NCT02555007Phase 1Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Aug 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vinorelbine in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Treatment-related hematological toxicities (neutropenia) of grade 3-4 at 24 months and Objective Response Rate at 24 months. Started Aug 2015; status: completed.
02
Drugs
vinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02555007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555007.